Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Randomised, Double-blind, Placebo Controlled, Study of MR901 in Patients With Moderate to Severe Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)

NCT02326454 is registered in ClinicalTrials.gov with Light Sciences Oncology as lead sponsor.

NCT NCT02326454
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02326454 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Randomised, Double-blind, Placebo Controlled, Study of MR901 in Patients With Moderate to Severe Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
Lead sponsor
Light Sciences Oncology
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2014
Completion date
March 29, 2017
Enrollment
225 (actual)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

benign prostatic hyperplasia